JP Morgan Chase
OTLK icon

JP Morgan Chase’s Outlook Therapeutics OTLK Stock Holding History

JP Morgan Chase’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5K Buy
7,970
+7,955
+53,033% +$4.93K ﹤0.01% 6837
2026
Q1 		$3 Hold
15
– – ﹤0.01% 7467
2025
Q4 		$24 Hold
15
– – ﹤0.01% 7296
2025
Q3 		$16 Hold
15
– – ﹤0.01% 7297
2025
Q2 		$24 Sell
15
-8,388
-100% -$13.4K ﹤0.01% 6947
2025
Q1 		$10.3K Buy
8,403
+914
+12% +$1.6K ﹤0.01% 6303
2024
Q4 		$14.2K Buy
7,489
+343
+5% +$1.41K ﹤0.01% 6316
2024
Q3 		$38.2K Buy
7,146
+3,595
+101% +$26.3K ﹤0.01% 6067
2024
Q2 		$26.2K Sell
3,551
-150
-4% -$1.2K ﹤0.01% 6072
2024
Q1 		$44.2K Sell
3,701
-1,338
-27% -$10.8K ﹤0.01% 5994
2023
Q4 		$39.7K Hold
5,039
– – ﹤0.01% 6066
2023
Q3 		$22.3K Sell
5,039
-987
-16% -$21.8K ﹤0.01% 6044
2023
Q2 		$210K Buy
6,026
+90
+2% +$2.45K ﹤0.01% 5045
2023
Q1 		$129K Buy
5,936
+2,571
+76% +$57.5K ﹤0.01% 5314
2022
Q4 		$72K Buy
3,365
+129
+4% +$2.81K ﹤0.01% 5482
2022
Q3 		$79K Buy
3,236
+67
+2% +$1.56K ﹤0.01% 5393
2022
Q2 		$65K Buy
3,169
+496
+19% +$14.3K ﹤0.01% 5577
2022
Q1 		$95K Buy
2,673
+949
+55% +$29.6K ﹤0.01% 5535
2021
Q4 		$47K Sell
1,724
-567
-25% -$20.2K ﹤0.01% 5971
2021
Q3 		$100K Buy
2,291
+610
+36% +$29.4K ﹤0.01% 5568
2021
Q2 		$84K Buy
+1,681
New +$78K ﹤0.01% 5599

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM

JP Morgan Chase's OTLK Position: Q2 2026 in Review

JP Morgan Chase increased its Outlook Therapeutics (OTLK) stake by 53,033% in Q2 2026, buying an estimated $4.93K and bringing the position to 7,970 shares worth $13.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6837.

JP Morgan Chase first reported a position in OTLK in Q2 2021 and has held it in 21 quarters since. The position peaked at $210K in Q2 2023. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • JP Morgan Chase held 7,970 shares of Outlook Therapeutics worth $13.5K as of Q2 2026.
  • JP Morgan Chase bought 7,955 Outlook Therapeutics shares in Q2 2026, an estimated $4.93K.
  • Outlook Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6837 holding.
  • JP Morgan Chase first reported a position in Outlook Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • JP Morgan Chase's Outlook Therapeutics position peaked at $210K in Q2 2023.
  • 69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.